Tirzepatide (Mounjaro®): A new treatment option for managing obesity
NHS Birmingham and Solihull and Black Country ICBs are providing Tirzepatide (Mounjaro®) for the management of obesity for an eligible cohort of people who meet the following criteria.
- Age 18+ and have a BMI of 35 or more (or 32.5 or more for people from minority ethnic backgrounds),
And have at least four of the five following long-term conditions:
- Type 2 diabetes
- High blood pressure (hypertension)
- Cardiovascular disease
- Dyslipidaemia
- Obstructive sleep apnoea
This is in line with national NHS England guidance and NICE recommendations.
If you have previously accessed Tirzepatide through a private provider, the NHS may only continue treatment if you meet the current NHS eligibility criteria following an assessment by the Integrated Care Board’s commissioned weight management service or by an appropriately trained health care professional within your GP practice
If you do not meet the current eligibility criteria, you will be advised of this. Whilst we recognise this may be disappointing, it's important to note there are other NHS services that can support you. These may include:
- Tier 2 weight management programmes
- Dietitian referrals
- Digital tools and lifestyle coaching
Please be aware if you contact an NHS service with questions about your private tirzepatide prescription, including stopping or tapering off the drug, you will be advised to speak with your private provider.
You can find out more information in our Frequently Asked Questions here.
